Telix的前列腺癌药物Illuccix在中国病人身上表现出很强的结果,在中国和美国增加了获得批准的机会。 Telix's prostate cancer drug Illuccix shows strong results in Chinese patients, boosting chances for approval in China and U.S.

Telix制药公司报告说,在中国病人中,其前列腺癌症成像剂Illucex在第三阶段的试验结果是积极的,实现了94.8%的正预测值,并促使三分之二以上的参与者改变了治疗方式。 Telix Pharmaceuticals reports positive Phase 3 trial results for its prostate cancer imaging agent Illuccix in Chinese patients, achieving a 94.8% positive predictive value and prompting treatment changes in over two-thirds of participants. 涉及140名病人的这一试验表明,在转移地点和PSA水平方面表现良好。 The trial, involving 140 patients, showed strong performance across metastatic sites and PSA levels. 成果支持了即将在中国实施的药物应用,这是前列腺癌诊断的日益增长的市场。 Results support an upcoming drug application in China, a growing market for prostate cancer diagnostics. 同时,Telix正在重新申请美国另外两个成像剂,林业发展局预计将很快审查这些成像剂。 Meanwhile, Telix is resubmitting applications for two other imaging agents in the U.S., with the FDA expected to review them soon.